FDA Accepts Bristol Myers' Mezigdomide Application, Sets May 2027 Decision Date
BMY sits 35% above its 52-week low of $42.52.
Summary
The FDA accepted Bristol Myers' application for mezigdomide in relapsed/refractory multiple myeloma, with a target action date of May 13, 2027. This follows positive Phase 3 SUCCESSOR-2 data reported in late May, which showed strong efficacy. The acceptance formalizes the regulatory path for a key pipeline asset in a competitive space—Takeda's zasocitinib recently outperformed Bristol's Sotykt in psoriasis, underscoring the need for new growth drivers. Mezigdomide, a CELMoD agent, could become the second approved drug in its class after iberdomide, which has an August 17 PDUFA date. The 2027 decision is a long-term catalyst, but the acceptance itself reduces regulatory uncertainty and validates the clinical data package.
At the time of this announcement, BMY was trading at $57.57 on NYSE in the Life Sciences sector, with a market capitalization of approximately $117.6B. The 52-week trading range was $42.52 to $62.89. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.